Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). If approved, Roche says, it would be the first Bruton’s tyrosine kinase (BTK) inhibitor for both forms.
Fenebrutinib Approval Timeline: What the FDA Has Said
No decision date has been published. Roche’s release names no action date and does not mention an EU filing. The FDA says its priority review goal is action within six months, against ten months under standard review. That page does not say when the clock starts for a given application.
A fenebrutinib approval date therefore cannot be calculated from public documents. Any specific month is an estimate. Roche has not published the information needed to narrow the range. Neither Roche’s release nor its investor update states a date. Roche’s third-quarter results on 22 October also give none. The FDA decision would also be separate from UK access. That depends on other regulators and on NICE.
What Did the FDA Accept?
Roche’s application rests on three phase 3 studies. FENhance 1 and FENhance 2 tested fenebrutinib in RMS against teriflunomide. FENtrepid tested it in PPMS against ocrelizumab, sold as Ocrevus. Roche says Ocrevus is the only approved PPMS treatment.
Acceptance for review is not approval. Roche’s release uses the phrase “if approved” throughout. Levi Garraway, Roche’s chief medical officer, said the studies show “the potential” for fenebrutinib. It could “address both relapsing and progressive disease”, Garraway said. Roche cites more than 3 million people with MS worldwide, and nearly 1 million in the United States.
What Do the Phase 3 Results Show?
Relapsing MS: FENhance 1 and 2
The two studies enrolled 1,497 adults in total. Participants took fenebrutinib twice daily or teriflunomide once daily for at least 96 weeks. The relapse data therefore reflect at least two years of treatment. A Genentech release dated 21 April 2026 reports results. Fenebrutinib cut the annualised relapse rate by 51.1 per cent in FENhance 1. The reduction was 58.5 per cent in FENhance 2.
Roche equates this to about one relapse every 17 years. Jiwon Oh, of St. Michael’s Hospital, University of Toronto, called the result a first. A BTK inhibitor had shown superiority “in reducing relapses and formation of new brain lesions”, Oh said. Oh directs the Barlo Multiple Sclerosis Program there. The comment appears in the sponsor’s release.
These figures come from the sponsor. Each trial compared fenebrutinib with teriflunomide only. Roche also reports fewer active and chronic brain lesions.
It describes disability results in each trial as “consistent positive trends”. A pooled analysis of both trials was presented at MSToronto2026 on 21 October. It reported a 16 per cent reduction in 12-week composite confirmed disability progression (p=0.04). That is a pooled finding rather than a result from either trial alone. These results underpin the fenebrutinib approval request.
Primary progressive MS: FENtrepid
FENtrepid met its primary endpoint of non-inferiority to ocrelizumab for disability progression. Roche reports a hazard ratio of 0.88, with a 95 per cent confidence interval of 0.75 to 1.03. The interval includes 1.0. The result is therefore a numerical difference, not a proven advantage. Roche’s release gives no trial size for FENtrepid.
What Do the Safety Data Show?
Safety is the main open question for any fenebrutinib approval. The sponsor’s figures contain both favourable and unfavourable findings, and both matter.
On the favourable side, serious adverse events were similar in FENhance 1. They were 8.6 per cent with fenebrutinib and 8.9 per cent with teriflunomide. In FENtrepid they were 19 per cent in both arms. In FENhance 2, liver enzyme elevations above three times normal limits were 5.6 per cent in each arm.
Other findings point the other way. In FENhance 1, such elevations occurred in 7.3 per cent on fenebrutinib and 5.7 per cent on teriflunomide. Roche describes liver enzyme rises in the relapsing MS trials overall as comparable with teriflunomide. Serious adverse events in FENhance 2 were 11.2 per cent against 6.1 per cent. Roche says liver enzyme elevations were seen more often with fenebrutinib than with ocrelizumab in FENtrepid. The release gives no figure.
FENhance 1 also recorded one Hy’s law case in each arm. Roche says the fenebrutinib case occurred before biweekly liver monitoring began. Both were asymptomatic and resolved after the study drug stopped. BioPharma Dive describes Hy’s law as a threshold that indicates higher risk of death or liver transplant.
Deaths are the sharpest concern. Across FENhance 1 and 2, seven deaths (0.9 per cent) occurred on fenebrutinib in the reporting period. One death (0.1 per cent) occurred on teriflunomide. The April release noted one further death after that period. BioPharma Dive counts eight deaths among fenebrutinib recipients.
Causes listed for the fenebrutinib deaths included neurocryptococcosis, pneumonia, type 1 diabetes complications, serious bleeding, suicide and accidental injury. One cause was unknown. Roche says the deaths “occurred at different timepoints and had various causes”. It also acknowledges an imbalance in reported fatalities across the three pivotal studies. BioPharma Dive reports that a partial clinical hold earlier slowed development.
Where Does the Class Stand After Tolebrutinib?
Sanofi’s tolebrutinib offers the nearest comparison for any BTK inhibitor decision in MS. Sanofi said on 24 December 2025 that the FDA had issued a complete response letter in non-relapsing secondary progressive MS. Sanofi announced on 23 June 2026 that the European Commission had approved it as Cenrifki.
The EU indication is secondary progressive MS without relapses in the last two years. Sanofi’s release describes drug-induced liver injury as an identified risk and stresses liver monitoring. Fenebrutinib is filed for different populations, so the cases are not directly comparable. Whether the FDA applies the same liver caution to fenebrutinib is not yet known. That judgement will shape any fenebrutinib approval and its label.
Could UK Patients Get Fenebrutinib?
UK access depends on a separate MHRA authorisation and a NICE appraisal. NICE lists two fenebrutinib topics: ID6577 for RMS and ID6543 for PPMS. Both show as awaiting development, with the publication date to be confirmed.
NICE says it was asked to appraise fenebrutinib “within its marketing authorisation”. The pages say the appraisals were rescheduled after company advice “to align with latest regulatory expectations”. NICE had anticipated a start in late August 2026. The pages do not say whether that start has happened.
A search of the emc medicines database on 22 October 2026 returned no fenebrutinib product. The practical sequence is a UK authorisation first, then NICE guidance. The label would therefore set the question NICE answers. UK timing for fenebrutinib approval stays open. An earlier article on bepirovirsen NHS access follows the same UK route for a hepatitis B medicine.
What Would Settle the Question?
Four events would answer the timing question. First, Roche could disclose the FDA action date. Second, the FDA decision would confirm approval status and label wording, including any liver monitoring. Third, an EU or UK filing announcement would start the EU or UK review clock. Fourth, NICE could publish a timetable.
Each step would come from the sponsor or a regulator, so each can be checked against a primary source. Readers following the story should watch those four markers rather than trade-press estimates.
The FDA drug approval decisions tracker on this site will list a date if one is published. Until then, the verified position is narrow. The FDA is reviewing the application. Roche still calls the drug investigational. A search on 22 October 2026 found no approval in any market. The deaths and liver findings remain the main uncertainty for fenebrutinib approval.
